Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.

Literature DB >> 25679292

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.

M M Patnaik, E A Wassie, E Padron, F Onida, R Itzykson, T L Lasho, O Kosmider, C M Finke, C A Hanson, R P Ketterling, R Komrokji, A Tefferi, E Solary.

Abstract

Entities: Disease Species

Year: 2015 PMID： 25679292 PMCID： PMC4349260 DOI： 10.1038/bcj.2015.9

Source DB: PubMed Journal: Blood Cancer J ISSN： 2044-5385 Impact factor: 11.037

× No keyword cloud information.

Correction to: Blood Cancer Journal (2015) 4, e270; doi:10.1038/bcj.2014.90; published online 2 January 2015 Since publication, the publishers have identified that this article was incorrectly placed in volume 4. The article belongs in volume 5. The publishers would like to apologise for any inconvenience caused. The article has been rectified and now carries the correct information.

11 in total

1. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.

Authors: M Jawhar; J Schwaab; S Schnittger; M Meggendorfer; M Pfirrmann; K Sotlar; H-P Horny; G Metzgeroth; S Kluger; N Naumann; C Haferlach; T Haferlach; P Valent; W-K Hofmann; A Fabarius; N C P Cross; A Reiter
Journal: Leukemia Date: 2015-10-14 Impact factor: 11.528

2. TET2 mutations were predictive of inferior prognosis in the presence of ASXL1 mutations in patients with chronic myelomonocytic leukemia.

Authors: Yajuan Cui; Hongyan Tong; Xin Du; Bing Li; Robert Peter Gale; Tiejun Qin; Jinqin Liu; Zefeng Xu; Yue Zhang; Gang Huang; Jie Jin; Liwei Fang; Hongli Zhang; Lijuan Pan; Naibo Hu; Shiqiang Qu; Zhijian Xiao
Journal: Stem Cell Investig Date: 2016-09-23

Review 3. Chronic myelomonocytic leukemia diagnosis and management.

Authors: Onyee Chan; Aline Renneville; Eric Padron
Journal: Leukemia Date: 2021-03-13 Impact factor: 11.528

Review 4. Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management.

Authors: Mrinal M Patnaik; Ayalew Tefferi
Journal: Am J Hematol Date: 2018-06 Impact factor: 10.047

Review 5. Genomic Landscape and Risk Stratification in Chronic Myelomonocytic Leukemia.

Authors: Anthony Hunter; Eric Padron
Journal: Curr Hematol Malig Rep Date: 2021-03-03 Impact factor: 3.952

Review 6. CMML: Clinical and molecular aspects.

Authors: Raphael Itzykson; Matthieu Duchmann; Nolwenn Lucas; Eric Solary
Journal: Int J Hematol Date: 2017-04-28 Impact factor: 2.490

7. Venetoclax/decitabine for a pediatric patient with chronic myelomonocytic leukemia.

Authors: John C Molina; Julie M Asare; Laura Tuschong; Robert R West; Katherine R Calvo; Rebecca Persky; Alison M Boyce; Dima A Hammoud; Steven M Holland; Dennis Hickstein; Nirali N Shah
Journal: Pediatr Blood Cancer Date: 2020-12-27 Impact factor: 3.838